Philip A. Philip

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle, Maeve A. Lowery, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2017 · 715 citations

Medicine, Oncology, Pharmacology +15

Up-regulation of <i>miR-200</i> and <i>let-7</i> by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

Yiwei Li, Timothy VandenBoom, Dejuan Kong et al. · Cancer Research · 2009 · 658 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Philip A. Philip, Jacqueline Benedetti, Christopher L. Corless et al. · Journal of Clinical Oncology · 2010 · 628 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

Philip A. Philip, Michelle R. Mahoney, Cristine Allmer et al. · Journal of Clinical Oncology · 2005 · 459 citations · Full text

Medicine, Oncology, Pharmacology +15